Loading...
•
Jun 30, 2022
Supernus Q2 2022 Earnings Report
Reported a 20% increase in total revenues compared to Q2 2021.
Key Takeaways
Supernus Pharmaceuticals, Inc. announced its Q2 2022 financial results, with total revenues of $170.1 million, a 20% increase compared to Q2 2021. The company reported GAAP operating earnings of $11.3 million and non-GAAP operating earnings of $37.6 million. Qelbree prescriptions continued to grow, with a 33% increase compared to Q1 2022.
Total revenues reached $170.1 million, a 20% increase compared to Q2 2021.
GAAP operating earnings were $11.3 million; non-GAAP operating earnings were $37.6 million.
Qelbree prescriptions increased by 33% compared to Q1 2022, totaling 62,938 prescriptions.
GOCOVRI prescriptions reached 10,929, a 16% growth compared to Q2 2021.
Revenue by Segment
Forward Guidance
The company reiterates its prior financial guidance for full year 2022.
Positive Outlook
- Total revenues are expected to be between $640 million and $680 million.
- Combined R&D and SG&A expenses are projected to be between $460 million and $490 million.
- Operating earnings are anticipated to be between $20 million and $40 million.
- Non-GAAP operating earnings are expected to be between $130 million and $165 million.
- Includes amortization of intangible assets and contingent consideration expense (gain).
Challenges Ahead
- Operating earnings include amortization of intangible assets.
- Operating earnings include contingent consideration expense (gain).
- R&D and SG&A expenses are expected to be significant.
- Amortization of intangible assets is projected to be between $80 million and $85 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...